DRTSW
Alpha Tau Medical Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$4.19
+6.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | 1.2M | — | — | — |
| Gross Profit | — | (1.2M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 38.8M | 30.8M | 27.0M | 26.4M | 20.9M |
| SG&A Expense | 11.7M | 10.2M | 9.0M | 9.3M | 11.2M |
| General & Admin Expense | 8.2M | 8.4M | 6.7M | 7.3M | 10.3M |
| Selling & Marketing Expense | 1.0M | 1.9M | 2.3M | 1.9M | 974.0K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 50.4M | 41.1M | 36.0M | 35.7M | 32.1M |
| Cost and Expenses | 50.4M | 42.3M | 36.0M | 35.7M | 32.1M |
| Operating Income (EBIT) | (50.4M) | (42.3M) | (36.0M) | (35.7M) | (32.1M) |
| Non-Operating | |||||
| Interest Income | — | 3.8M | 4.3M | 4.8M | 1.8M |
| Interest Expense | 41.4M | 419.0K | 303.0K | 75.0K | — |
| Net Interest Income | (41.4M) | 3.4M | 4.0M | 4.8M | 1.8M |
| Other Non-Op Income/Expense | (42.0M) | (218.0K) | 4.3M | 6.5M | (1.6M) |
| Non-Operating Income (excl Interest) | (129.0K) | — | (4.6M) | (6.6M) | 1.6M |
| EBT (Pre-Tax Income) | (92.4M) | (42.5M) | (31.7M) | (29.1M) | (33.7M) |
| Income Tax Expense | 175.0K | 121.0K | 6.0K | 16.0K | 20.0K |
| Bottom Line | |||||
| Net Income | (92.6M) | (42.6M) | (31.8M) | (29.2M) | (33.8M) |
| Earnings from Cont. Ops | (92.6M) | (42.6M) | (31.8M) | (29.2M) | (33.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (92.6M) | (42.6M) | (31.8M) | (29.2M) | (33.8M) |
| Per Share | |||||
| Basic EPS | ($1.04) | ($0.53) | ($0.45) | ($0.42) | ($0.53) |
| Diluted EPS | ($1.04) | ($0.53) | ($0.45) | ($0.42) | ($0.53) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 91.0M | 80.6M | 69.9M | 69.4M | 63.5M |
| Diluted Shares Outstanding | 91.0M | 80.6M | 69.9M | 69.4M | 63.5M |
| Profitability Metrics | |||||
| EBITDA | (49.1M) | (41.1M) | (30.3M) | (28.0M) | (32.8M) |
| D&A | 1.2M | 1.2M | 1.1M | 1.1M | 979.0K |
| EBIT | (50.3M) | (42.3M) | (31.4M) | (29.1M) | (33.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026